Nations Royalty Corp. Upsizes Private Placement to C$13 Million Amid Strong Demand

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Jan 16 2026

0mins

NRC+0.06%

Should l Buy NRC?

Source: Yahoo Finance

Increased Financing Size: Nations Royalty Corp. has agreed with Red Cloud Securities to upsize its previously announced private placement from C$10 million to C$13 million, reflecting strong investor demand and expected to enhance the company's capital strength for future acquisitions.
Unit Issuance Details: The upsized offering will issue 8.125 million units at a price of C$1.60 each, consisting of one common share and half a warrant, with warrants exercisable at C$2.25 within 36 months, thereby increasing potential returns for investors.
Over-Allotment Option: The company has granted underwriters an option to purchase up to an additional 1.25 million units, potentially raising an extra C$2 million, which adds flexibility and enhances the attractiveness of the financing.
Clear Use of Proceeds: The company intends to use the net proceeds for acquiring royalties, income, and commodity streams, as well as for working capital, demonstrating its strategic positioning in resource projects and confidence in future growth.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy NRC?" and start using high-conviction signals backed by rigorous historical data.

NRC

$15.94+Infinity%1D

Analyst Views on NRC

About NRC

National Research Corporation, doing business as NRC Health, is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States. Its digital solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience, which can be implemented both collectively as an enterprise solution or individually to meet specific needs within the organization. Its Marketing solutions are subscription-based services that allow for improved tracking of awareness, perception, and consistency of healthcare brands; real-time assessment of competitive differentiators, and enhanced segmentation tools. Its Reputation solutions allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs better consumer decision-making.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

National Research Corporation Q4 2025 Earnings Call Highlights

5 days agoseekingalpha

Revenue and EBITDA Performance: In Q4 2025, NRC reported revenue of $35 million and adjusted EBITDA of $9 million, showing a 5% year-over-year decline but a 2% sequential increase, indicating a gradual recovery amidst challenging comparisons.
Sustained Contract Value Growth: Total Recurring Contract Value (TRCV) reached $144.1 million, up 8% year-over-year, marking the fifth consecutive quarter of sequential TRCV growth, reflecting strong execution from the sales and customer success teams.
Leadership Changes and Strategy: The company welcomed David Burik as the new head of strategic insights and governance in January, bringing over 30 years of healthcare consulting experience, which is expected to enhance strategic decision-making in governance and system transformation.
Future Growth Outlook: CEO Green highlighted that the go-to-market restructuring and enablement will be key growth catalysts for 2026, anticipating further revenue and margin expansion, particularly driven by advancements in AI technology.

National Research Q4 Financial Highlights

5 days agoseekingalpha

Earnings Per Share: National Research reported a Q4 Non-GAAP EPS of $0.16, indicating stable profitability despite uncertainties in the overall market environment.
Revenue Growth: The company achieved Q4 revenue of $35.2 million, showing an increase compared to the previous year, reflecting its competitive position and rising customer demand.
Net Income Analysis: GAAP net income stood at $1.8 million, representing 5% of total revenue, while adjusted net income was $3.4 million, or 10% of revenue, highlighting improvements in cost control and profitability.
Adjusted EBITDA: Adjusted EBITDA reached $8.7 million, accounting for 25% of revenue, indicating enhanced operational efficiency and providing financial support for future investments and expansion.

National Research Declares Quarterly Dividend of $0.16

5 days agoseekingalpha

Quarterly Dividend Announcement: National Research has declared a quarterly dividend of $0.16 per share, consistent with previous distributions, indicating the company's ongoing ability to maintain stable cash flow.
Dividend Yield: The forward yield of 2.92% provides investors with a relatively stable return, enhancing the attractiveness of the company's stock in the market.
Payment Schedule: The dividend will be payable on April 10, with a record date of March 27 and an ex-dividend date also on March 27, ensuring shareholders receive their earnings promptly.
Investor Confidence: By maintaining the dividend level, National Research signals confidence in its financial health, potentially attracting more investors seeking stable income.